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Background: Neoadjuvant chemotherapy (NC) is an established therapy in breast cancer, able to downstage
positive axillary lymph nodes, but might hamper their detectibility. Even if clinical observations suggest lower
lymph node yield (LNY) after NC, data are inconclusive and it is unclear whether NC dependent parameters
influence detection rates by axillary lymph node dissection (ALND).
Methods: We analyzed retrospectively the LNY in 182 patients with ALND after NC and 351 patients with primary
ALND. Impact of surgery or pathological examination and specific histomorphological alterations were evaluated.
Outcome analyses regarding recurrence rates, disease free (DFS) and overall survival (OS) were performed.
Results: Axillary LNY was significantly lower in the NC in comparison to the primary surgery group (median 13 vs.
16; p < 0.0001). The likelihood of incomplete axillary staging was four times higher in the NC group (14.8% vs. 3.4%,
p < 0.0001). Multivariate analyses excluded any influence by surgeon or pathologist. However, the chemotherapy
dependent histological feature lymphoid depletion was an independent predictive factor for a lower LNY. Outcome
analyses revealed no significant impact of the LNY on local and regional recurrence rates as well as DFS and OS,
respectively.
Conclusion: NC significantly reduces the LNY by ALND and has profound effects on the histomorphological
appearance of lymph nodes. The current recommendations for a minimum removal of 10 lymph nodes by ALND
are clearly compromised by the clinically already established concept of NC. The LNY of less than 10 by ALND after
NC might not be indicative for an insufficient axillary staging.
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Axillary lymph node status is one of the most powerful
prognostic factors in breast cancer (BC) [1-3] and ALND
the standard approach for local staging in lymph node
positive patients. There is some evidence for an inverse
correlation between a low number of removed axillary
lymph nodes (often <10) and overall survival [4-10],
which is controversially discussed [11-13].
Surgical staging of the axilla, particularly the number
of positive lymph nodes is still a major driver for local* Correspondence: elmar.stickeler@uniklinik-freiburg.de
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reproduction in any medium, provided the orand systemic treatment decisions. Therefore current
guidelines recommend the removal of at least 10 lymph
nodes [1,14], based on a mathematical model which de-
termined the cut off at 10 lymph nodes to allow a 90%
certainty of a true negative axillary status [14,15].
NC has become a common treatment for patients with
locally advanced and lymph node positive BC. NC is able
to downstage the number of involved axillary lymph
nodes [16] as an important parameter in the definition
of the pathological complete response (pCR). Clinical
observations suggest a lower LNY after NC, which might
be due to chemotherapy dependent parameters influen-
cing detection rates. Therefore we examined these po-
tential effects of NC by comparing retrospectively LNYtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mary surgery versus NC and analysed its potential im-
pact on clinical outcome.
Methods
Patients
We selected retrospectively 533 patients with primary
BC from the database of the Department of Gynaecology
and Obstetrics, University Medical Center Freiburg,
who underwent ALND (Level 1 and 2) or sentinel
node biopsy (SLNB) plus ALND from January 2001 to
December 2010. Bilateral BC was excluded. All patients
in the study had a histological proven axillary metastasis.
The distinct algorithm for the confirmation of axillary
involvement was a follows: In the case of a clinical suspi-
cious axilla (91.8%, 167/182) the lymph nodes status was
evaluated by core biopsies of distinct nodes before NC.
With the proven lymph node metastasis patients under-
went the consecutive NC. In the case of a clinical nega-
tive axilla, patients (8.2%, 15/182) underwent sentinel
lymph node biopsy before NC.
Finally all patients (182(182) underwent the consecutive
ALND after NC. The 182 patients receiving NC were
defined as the primary chemotherapy group (PCG), who
underwent consecutive surgery with standard ALND. Pa-
tients who received SLNB (15 patients, 8.2%) before NC
and ALND after completion because of positive sentinel
nodes were also included (total count including both senti-
nel and non-sentinel nodes, respectively). All patients re-
ceived an anthracycline and/or taxane-based chemotherapy
regime. Initial tumor size (Table 1) as well as response to
NC was routinely measured by ultrasound. The primary
surgery group (PSG; n = 351) was initially treated with
primary surgery including standardized ALND, or SLNB
(n = 193, 55.0%) and ALND because of positive sentinel
node. Surgeries in both groups were performed by qualified
breast surgeons according to a standardized protocol which
is based on the national S3 guidelines and contains the
comprehensive removal of the axillary tissue of the level 1
and 2 [17]. The influence of the individual surgeon on the
LNY was evaluated.
Patients and tumor characteristics including age, size,
histological subtype, stage, nodal status, grading, lym-
phovascular invasion, estrogen, progesterone and Her2
receptor status, menopausal status and type of surgery
were evaluated (Table 1). The tissue specimens were an-
alyzed by 19 pathologists and the potential impact of the
individual investigator on LNY separately analyzed. All
lymph nodes were processed and analyzed by a stan-
dardized protocol according to the current national S3
guidelines, and inconclusive cases were subjected to im-
munohistochemistry (IHC) [17]. Sentinel nodes were
serially sectioned, and submitted to hematoxylin-eosin
as well as IHC against pancytokeratin.A consecutive series of 94 lymph nodes from PCG and
97 from PSG, respectively, were re-evaluated for differ-
ences regarding the following histological features: me-
dian size, capsular invasion, diffuse fibrosis, lymphoid
depletion, B-and T-cell accentuated depletion, signs of
bleeding and calcification.
Outcome analyses regarding local, regional and distant
recurrences as well as 5 year DFS and OS were per-
formed for all subgroups of patients in regards to LNY,
axillary response and histomorphological features, re-
spectively. These data consider the consecutive treat-
ment in both groups, which presented equally balanced
with comparable endocrine as well as radiation therapy
rates (data not shown).
Statistical analyses
Lymph node counts were described by medians and
quartiles and compared between groups using Wilcoxon’s
test. For univariate comparisons between groups,
Welch’s t-test (for continuous variables) and Pearson’s
Chi square test (for nominal variables) were used. For de-
scriptive aims, box plots were produced. Further, lymph
node counts were analyzed in a multivariable Poisson re-
gression analysis to adjust for a number of pre-specified
covariates. Time-to-event endpoints were analyzed using
Cox’s regressions model, and five-year event free rates
with confidence intervals were taken from the regression-
based survival functions. The significance level was set
to alpha = 0.05. Data analysis was performed by open
statistical software environment R (R Development Core
Team, “R: A Language and Environment for Statistical
Computing”. R foundation for Statistical Computing,
2009. URL http://www.R-project.org).
Results
We included 182 patients receiving NC, and 351 pa-
tients receiving primary surgery into this retrospective
analysis. Significant differences were seen in a variety of
baseline criteria between the two groups, since treat-
ment decisions in regards to NC are routinely based on
tumor size, clinical nodal involvement, grading, age and
receptor status, though no significant difference in the
histological tumor type was seen (Table 1).
Our analyses revealed a significantly lower LNY in pa-
tients undergoing NC in comparison to patients who did
not. With a median total number of 13 nodes (interquar-
tile range 11–17) in the PCG compared to 16 axillary
nodes in the PSG (interquartile range 13–20), these
results were highly statistically significant (p < 0.0001;
Figure 1). Since the removal of at least 10 axillary nodes
represents the gold standard for systematic axillary sta-
ging, we dichotomized the number of removed lymph
nodes using 10 nodes as the cut-off. The analysis found
a significantly higher number of patients (27 pts., 14.8%)
Table 1 Patients and tumor characteristics
Characteristic PCG PSG P value
N % N %
N 182 351
Mean age (range), y 49.82 (28–69) 60.33 (28–87) < 0.0001
Mean tumor size, (range), mm 33.02 (0–100) 25.40 (2–89) < 0.0001
Histology 0.219
Invasive ductal 151 82.9 270 76.9
Invasive lobular 21 11.5 60 17.0
Others 10 5.5 21 5.9
Tumor stage <0.0001
T1 22 12.0 156 44.4
T2 116 63.7 157 44.7
T3 19 10.4 26 7.4
T4 25 13.7 12 3.4
Nodal status <0.0001
pN0 82 45.1 54 15.4
pN1 63 34.6 189 53.8
pN2 37 20.3 108 30.8
Grading 0.0062
G1 6 3.3 9.9
G2 119 65.4 219 62.4
G3 57 31.3 97 27.6
Lymphovascular <0.0001
invasion
L0 131 71.8 168 47.9
L1 51 28.0 183 52.1
Hormone receptor 0.004
status
ER positive 131 71.9 261 74.3
PR positive 96 52.7 225 64.1
Menopausal status <0.0001
Premenopausal 78 42.6 92 26.2
Postmenopausal 104 57.1 259 73.8
Mastectomy 0.010
Yes 76 42.3 189 53.8
No 106 57.7 162 46.2
HER2neu status 0.003
Positive 47 25.8 53 15.0
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parison to 12 patients (3.4%) in the PSG (p < 0.0001).
As expected the number of patients with involved lymph
nodes was significantly lower in PCG (100/182, 54.9%)
compared to the PSG (297/351, 84.6%; p < 0.0001). For the
PCG, status of lymph node positivity after NC at the time
of surgery did not influence the number of retrievedlymph nodes. We found a median total number of 13
lymph nodes (interquartile range 10–17) for patients
with nodal involvement compared to 14 nodes (inter-
quartile range 11–18) in patients without nodal involve-
ment (p = 0.654), respectively, (Table 2).
Furthermore the median number of involved nodes/
total nodes was comparable for both groups with a
Figure 1 Statistical analysis: total number of yielded axillary lymph nodes. The total number of detected nodes is shown by box plots for
the patients treated with neoadjuvant chemotherapy and primary surgery (P = 0.001, Wilcoxon’s test). Thick lines, median (50% percentile); gray
boxes, 25% to 75% percentile; thin lines, minimal and maximal value.
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the PCG and a median number of 2.5 involved nodes/17
total number of nodes in the PSG (p = 0.904), respect-
ively (Table 2).
After adjusting for age, menopausal status, histological
subtype, tumor size, grading, lymphovascular invasion, re-
ceptor status, HER2 status, mastectomy and NC, the multi-
variate Poisson regression analysis confirmed neoadjuvantTable 2 Influence of nodal involvement on total lymph node
Median total number of lymph






* interquartile range.treatment as the strongest independent factor for a lower
LNY after ALND (p < 0.0001). In addition, age represented
an independent factor with decreased LNY with increasing
age (p = 0.031; Table 3).
Since NC is employed for downstaging of local disease,
the LNY by ALND might be compromised by the re-
gression grade as treatment response. Regression was
classified by a semiquantitative scoring system accordingyield
Median total number of lymph





Table 3 Influence of clinico-pathological characteristics
total lymph node yield in 533 breast cancer patients
Variable Relative risk 95% CI P-value
Intercept 17.78123 15.26726 20.70916 0.00000
Group
Primary chemotherapy 0.83132 0.78241 0.88328 0.00000
Primary surgery 1.0*
Age (per year) 0.99735 0.99560 0.99911 0.00313
Mean tumor size 1.00051 0.99825 1.00277 0.65826
Histology
Invasive lobular 0.98133 0.91887 1.04803 0.57423
Others 0.99680 0.90075 1.10309 0.95052
Tumor stage
T2 0.96670 0.90878 1.02832 0.28274
T3 0.98958 0.86080 1.13762 0.88293
T4 0.86859 0.76246 0.98949 0.03410
T1 1.0
Nodal status
N1 0.99459 0.93456 1.05848 0.86435
N2 1.03164 0.95485 1.11461 0.42991
N0 1.0
Grading
G2 1.07546 0.98631 1.17266 0.09941
G3 1.10697 1.00705 1.21680 0.03525
G1 1.0
Hormone receptor status
ER positive 0.98314 0.91915 1.05160 0.62056
ER negative 1.0
PR positive 1.06930 1.00638 1.13616 0.03035
PR negative 1.0
HER2neu status
Positive 1.05745 0.99583 1.12288 0.06822
Negative 1.0
Type of breast surgery
Mastectomy 0.97233 0.92656 1.02036 0.25405
Breast conserving surgery 1.0
*reference value.
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tion and tumorsclerosis, 2 =minimal residual invasive
tumor < 0.5 cm, 3 = residual non-invasive tumor only,
4 = no tumor detectable). However, no correlation be-
tween the regression grade and LNY was found (data not
shown). An isolated view on the 28.6% (n = 52) patients
with an axillary pathological complete response (pCR) re-
vealed no influence of response on LNY (p = 0.615). Fur-
thermore the regional axillary recurrence rates werestatistically not different between these patients (1.9%) and
those (3.0%) who did not achieve an axillary pCR.
To evaluate the potential impact of the individual sur-
gery or pathological examination we also investigated
the dependence of LNY on the individual surgeon or
pathologist, respectively. Fifteen surgeons, with six per-
forming 75.8% of the ALNDs (404/533) and 19 patholo-
gists, with five main specialists, performing 81.2% of the
examinations (449/533), were involved. Univariate and
multivariate analyses confirmed the independence of the
LNY from individual surgeon pathologist as well as their
specific interactions (data not shown).
Since NC is known to alter histomorphology of lymph
nodes [18], including size and depletion of lymphocytes,
which could potentially compromise their detectability, we
investigated these features in more detail. In a consecutive
series of 191 lymph node specimens, from 94 patients of
PCG and 97 patients of PSG the histomorphological param-
eter median size, capsular invasion, diffuse fibrosis, lymph-
oid depletion, B-and T-cell accentuated depletion, signs of
bleeding and calcification, were evaluated respectively.
Diffuse fibrosis within a lymph node was defined and
scored as 0 = no presence, 1 = partial presence, 2 = clear
presence, 3 = strong presence of collagen fibers. Lymphoid
depletion was classified by the density of lymphocytes and
scored as 0 = no reduction, 1 = reduction up to 30%, 2 =
reduction up to 50%, 3 = reduction up to 90%, respectively.
The depletion was separately evaluated for a B-cell accen-
tuated depletion with a decrease in the B-cell zone or a
T-cell accentuated in the T-cell zone (interfollicular). Signs
of bleeding was defined as the appearance of macrophages
phagocytazing hemosiderin, or cholesterol crystals, re-
spectively, and scored as 0 = no macrophages, 1 = single
macrophages, 2 = up to 50%, 3 = up to 100% of the area.
The presence of calcification was defined as a sign of older
necrosis. All findings and their statistical analyses are sum-
marized in Table 4.
NC had a profound effect on the histomorphological
appearance of lymph nodes. The features diffuse fibrosis,
lymphoid depletion and signs of bleeding were more fre-
quent in the PCG, while the capsular invasion and lym-
phangiosis carcinomatosa due to the supposed treatment
effects were less frequent in comparison to the PSG.
However, the multivariate analysis identified solely the
parameter lymphoid depletion as an independent pre-
dictive factor for a lower LNY (Table 5), but not as a
predictor for a complete axillary response (p = 0.662).
To evaluate the clinical impact of these findings we
performed additional outcome analyses. The follow up
rates were 92.3% in the PCG and 91.5% in the PSG, re-
spectively. Local and regional recurrences were nearly
identical (Table 6) with a five-year local recurrence free
survival rate of 95.0% in the PCG and 94.8% in the PSG
(p = 0.944), respectively. However we detected significant
Table 4 Histomorphological criteria of lymph nodes
Characteristic PCG PSG P value
N N
N 94 97




























Table 5 Influence of histomorphological features on total
lymph node yield in a subgroup of consecutive 191
breast cancer cases
Variable Relative risk 95% CI P-value
Intercept 15.81943 14.28861 17.51425 0.00000
Group
Primary chemotherapy 0.94772 0.84264 1.06592 0.37055
Primary surgery 1.0*
Median lymph node size 0.99747 0.98930 1.00574 0.54908
Capsular invasion 0.90984 0.82697 1.00103 0.05251
Diffuse fibrosis
1 1.02911 0.91502 1.15743 0.63216
2 0.97344 0.81156 1.16761 0.77174
3 0.84740 0.69909 1.02717 0.09163
0 1.0
Lymphoid depletion
1 0.72503 0.59371 0.88540 0.00161
2 0.69376 0.52246 0.92123 0.01150
3 0.54756 0.33636 0.89139 0.01542
0 1.0
B-cell accentuated
1 1.11951 0.92850 1.34982 0.23691
0 1.0
T-cell accentuated
1 1.22733 1.06029 1.42068 0.00606
0 1.0
Signs of bleeding
1 0.89257 0.66532 1.19746 0.44844
2 1.92896 0.75390 4.93552 0.17049
3 0.81796 0.37759 1.77194 0.61041
0 1.0
Calcification
1 1.25871 0.92286 1.71677 0.14622
0 1.0
*reference value.
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tant metastasis free survival of 80.6% in the PCG and
91.5% in the PSG (p = 0.00113), respectively.
The five-year DFS(OS) was 77.0% (82%) for the PCG
and 80.1% (84.3%) (p = 0.412; (p = 0.547)) for the PSG,
respectively, (Table 6).
The subgroup analyses for the PCG with an incomplete
staged axilla (less than 10 nodes) did also not detect sig-
nificant differences for clinical outcome in regards to local,
regional and distant recurrences, respectively.
Discussion
It is well known that NC could result in downstaging of
positive axillary lymph nodes [16] but the potential influ-
ence of chemotherapy on the LNY and their morphology
and detectibility is still unclear. Since an incomplete axillarystaging might compromise further treatment modalities
(e.g. radiation therapy) and curation rates, we examined
over 500 patients in regards to this pertinent clinical ques-
tion. We were able to identify clearly NC as a significant
and independent factor for a reduced LNY (13 in the PCG
vs. 16 in the PSG; p < 0.0001) by ALND. Our findings are
in line with several smaller recently published studies which
found similar decreased numbers [19-21]. The outcome
analyses clearly indicated, that a reduced LNY did not affect
five-year DFS as well as OS.
The rate of suboptimal staged axillae with less than 10
lymph nodes was also significantly higher in the PCG
(14.8% vs. 3.4%; p < 0.0001). This phenomenon was also
Table 6 Clinical outcome depending on primary treatment




Local recurrence 8 14 0.9694 0.4066 2.3111 0.944
Regional recurrence 5 0 0.0000 0.0000 infinity 0.999
Distant recurrence 32 25 0.4194 0.2485 0.7077 0.001
End of disease-free survival 39 61 0.8453 0.5655 1.2633 0.412








95% confidence interval (CI) [74.6%; 87.2%] [88.3%; 94.8%]
Five-year disease free survival rate 77.0% 80.1%
95% confidence interval (CI) [70.7%; 83.8%] [75.7%; 84.9%]
Five-year overall survival rate 82.0% 84.3%
95% confidence interval (CI) [76.2%; 88.2%] [80.3%; 88.6%]
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to 45% [20], respectively. As an important aspect, we
could clearly exclude a negative effect on local, regional
and distant recurrence rates, as well as DFS and OS,
respectively.
Our two groups were significantly heterogeneous re-
garding a variety of baseline criteria, esp. tumor size and
clinical nodal involvement, which both were markedly
advanced in the PCG. This might be clinically reflected
by the fact, that the rate of distant metastases is signifi-
cantly higher in this group. The missing impact on OS
might be due to the relatively limited follow up. How-
ever, applying multivariate analyses, we could exclude a
significant influence of the described heterogeneity on
our findings. Noteworthy, the known effect of an in-
creasing age lowering the LNY [22], which was also sig-
nificant in our cohort, did not lead to a lower LNY in
our PSG, which was significantly older with a mean age
of 60.3 years versus 49.8 years for the PCG. These re-
sults support our hypothesis of NC as the strongest vari-
able for a diminished lymph node number.
The expertise of the individual surgeon as well as
pathologist on the LNY was considered a strong pre-
dictor for the LNY [20,22,23]. However, in our study
cohort multivariate analyses could not detect any signifi-
cant influence of lymph node retrieval by the involved
specialists as well as specific interactions between them.
These findings strongly support the suggested profound
impact of the NC itself on the lymph node detection fre-
quency. The biological effect of chemotherapy is clearly
visible by the detected downstaging effect with a lower
number of lymph node positive patients (54.9% vs.
84.6%; p < 0.0001) in the PCG. These findings are in linewith the NSABP-B18 trial, which found a comparable ef-
fect with lymph node metastasis in 41% neoadjuvant
treatment group compared to 57% in the postoperative
chemotherapy group [24]. Nevertheless, as a consistent
overall finding, axillary pCR did not alter the LNY in
our study or influenced the regional recurrences rates.
Still, it remains unclear, if the observed biological effects
of NC affect the histopathological work up and cause the
observed lower detection rates. We revealed significant
chemotherapy induced histomorphological changes within
lymph nodes regarding the features lymphoid depletion,
diffuse fibrosis, calcifications and signs of bleeding. Multi-
variate analyses identified lymphoid depletion as an inde-
pendent histomorphological parameter for a lower LNY
after NC. This might be explained by the fact that
lymphoid depletion will lead to shrinkage of lymph
nodes as well as to regression of lymphoid tissue. Both
effects could hamper their detectability. These findings
are in line with recently published studies which re-
ported also chemotherapy-induced changes in lymph
nodes including lymphoid depletion [18,25,26]. These
signs were suggested to be surrogates for previous
lymph node metastasis which responded completely to
therapy [27]. Clinically, this is of high importance, since
a broad number of studies have already correlated
clinical and pathologic primary tumor responses with
outcome [24,28-32]. However in our study, lymphoid
depletion was not associated with a higher axillary re-
sponse rate (pCR).
Since treatment response might be also an additional
potential factor affecting the LNY, our present study
evaluated also the pathological tumor response accord-
ing to Sinn by a standardized classification system for
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logically evaluated response rates had no significant im-
pact on LNY, specifically the axillary response rates did
not influence the LNY. Furthermore, axillary response
was no predictor for later axillary recurrence.
Conclusion
In conclusion, our study on more than 500 patients with
primary BC clearly identified NC as a significant inde-
pendent parameter for a reduced LNY by ALND. Fur-
thermore, the NC concept had profound effects on the
histomorphological appearance of lymph nodes. Lymph-
oid depletion was a strong independent factor for a
lower number of yielded axillary lymph nodes after NC.
These histological changes could hamper the detectabil-
ity of lymph nodes which was investigator independent.
However, the lower LNY had no impact on clinical out-
come. The still existing recommendations for a mini-
mum removal of 10 lymph nodes by ALND are clearly
compromised by the clinically already established con-
cept of NC. Consequently, the lymph node count of less
than 10 by ALND after NC is not indicative for an insuf-
ficient axillary staging. Therefore, guideline recommen-
dations for the future should consider the combination
of both innovative treatment modalities.
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